[Version 9,03/2022] corr. 11/2022

ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

MIPREPOL 20 mg/ml + 4.48 mg/ml + 0.5293 mg/ml cutaneous suspension/ear drops, suspension for dogs and cats (IT)
SUROLAN 20 mg/ml + 4.48 mg/ml + 0.5293 mg/ml cutaneous suspension/ear drops, suspension for dogs and cats (ES, PT)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

Active substances:
20 mg Miconazole (as nitrate)
4.48 mg Prednisolone (as acetate)
0.5293 mg Polymyxin B sulfate

Excipients:

Qualitative composition of excipients and other constituents
Silica colloidal anhydrous
Paraffin, liquid

White suspension.

3. CLINICAL INFORMATION

3.1 Target species
Dogs and cats

3.2 Indications for use for each target species
Dogs and cats: topical treatment of otitis externa and skin infections caused by the following susceptible species:

Fungi and yeasts
Microsporum spp
Trichophyton spp.
Candida spp.
Malassezia pachydermatis
Gram-positive bacteria
Staphylococcus spp.
Streptococcus spp.
Gram-negative bacteria
Pseudomonas spp.
Escherichia coli

In the case of external otitis due to ear mites (*Otodectes cynotis*), the effect of this product is due to a physical action of its excipient and not to the intrinsic activity of the active substances. Its use in this indication has to be chosen only when there is a secondary infection caused by susceptible organisms.

The product also has anti-inflammatory and anti-pruritic activity.

3.3 Contraindications
Do not use in animals with perforated ear drums since Polymixin B is known to be a potential ototoxic agent.
Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

3.4 Special warnings
Otitis is often secondary to primary causes which should be determined by an accurate diagnosis.

3.5 Special precautions for use
Special precautions for safe use in the target species:
For external use only.
Whenever possible, the veterinary medicinal product should only be used based on susceptibility testing.
Official, national and local antimicrobial policies should be taken into account when the product is used.
Use of the product deviating from the instructions given in the SPC may increase the prevalence of resistant bacteria, fungi or yeasts to polymixin B or miconazole respectively.

Before the product is applied, the external auditory canal must be examined to ensure that the eardrum is not perforated in order to avoid the risk of transmission of the infection to the middle ear and to prevent damage to the cochlear and vestibular apparatus.
After recovery, ears should be checked at regular intervals for signs of reinfection.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
In case of accidental contact with eyes, seek medical advice immediately and show the package leaflet or the label to the physician.
People with known hypersensitivity to the active substances should avoid contact with the veterinary medicinal product.
Personal protective equipment consisting of single use disposable gloves should be worn when handling the veterinary medicinal product.

The veterinary medicinal product should not be administered by pregnant women.

Special precautions for the protection of the environment:
Not applicable.

Other precautions:
This veterinary medicinal product does not contain any antimicrobial preservative.

3.6 Adverse events

Dogs and cats:

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Deafness[1,2], hearing decreased[2] Hypersensitivity or Allergic reaction[3]

[1] Mainly in elderly dogs. If this occurs, treatment should be stopped.
[2] Reversible in the majority of cases.
[3] May occur, to any of the active substances or excipients

Long-term use of topical corticosteroids may cause very rare local or systemic effect, including skin thinning and delay wound healing. Their immunosuppressant actions may weaken resistance to or exacerbate existing infections.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See also section 16 of the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:
Can be used during pregnancy and lactation.

3.8 Interaction with other medicinal products and other forms of interaction
None known.

3.9 Administration routes and dosage
For topical administration. Shake the bottle well before use.
At the beginning of treatment, hair surrounding or covering the lesions must be clipped; this should be repeated during treatment if necessary.

Ears:
Clean the auditory canal and place 3-5 drops of the product into the ear twice daily.
Massage the ear and the auditory canal gently but thoroughly to ensure proper distribution.
For infections caused *by Otodectes cynotis*, instill five drops twice daily for 14 days.

Skin: Having ensured the area to be treated is clean, apply a few drops of the product (depending on lesion size) twice a day. Wear single use disposable gloves and rub well.

Treatment should be continued until a few days after complete disappearance of the clinical symptoms. In some obstinate cases, treatment may be required for 2 to 3 weeks.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)
No data available. Do not exceed the recommended dosage.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance
Not applicable.

3.12 Withdrawal periods
Not applicable.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code:
QS02CA01

4.2 Pharmacodynamics
This product is a combination of three active substances: one antifungal, one antibiotic and one corticosteroid.

Miconazole nitrate is a synthetic imidazole derivative with a pronounced antifungal activity: it selectively inhibits the biosynthesis of ergosterol, damaging the fungal cell wall membrane and altering its permeability and causing the loss of the intracellular organelles and the inhibition of glucose use.
Miconazole is active against dermatophytes and yeasts and have a certain bactericidal activity against some Gram positive bacteria, i.e. *Staphylococcus* spp and *Streptococcus* spp.

Polymyxin B is a polypeptide antibiotic with bactericidal activity. It binds to phospholipids in the cytoplasmic membrane, altering the membrane permeability. This results in lysis of the bacteria. Polymyxin B is mainly active against Gram negative bacteria, including *Pseudomonas* spp. Resistance to polymyxin B is not frequent, but there is complete cross-resistance with colistin.

Prednisolone is a synthetic glucocorticoid related to cortisol with anti-inflammatory, anti-itch and antiallergenic activities. The anti-inflammatory action of prednisolone acetate results from its reduction of the permeability of capillaries and vascular proliferation and from the inhibition of the fibroblast action. Membranes of the liposomes are stabilized against hypoxia, toxins and others.

The fast relief from pain and itching as well as the reduction of local oedema and inflammation help in preventing secondary trauma or injuries caused by excessive licking, abrasions, violent head-scratching and bites.

4.3 Pharmacokinetics

Several laboratory experiments have shown that there is almost no systemic absorption through the skin or mucous membranes after topical application of miconazole nitrate and polymyxin B, and the absorption through damaged skin or other injuries is negligible.
The systemic absorption of prednisolone through intact or damaged skin is minimal.

The obstacle to the systemic absorption seems to be localised at the dermo-epidermal junction where it forms long-term deposits on the superficial layers of the epidermis with no significant systemic absorption.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

None known.
Avoid concomitant use with other topical products.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf life after first opening the immediate packaging: 3 months.

5.3 Special precautions for storage

Do not store above 25 °C.
Store in the original container.

5.4 Nature and composition of immediate packaging

LDPE squeeze dropper bottle of 15 ml or 30 ml with a screw cap.
LDPE bottle of 15 ml or 30 ml with squeeze dropper in thermoplastic elastomer and child resistant screw cap in HDPE.
Lithographed carton boxes together with the package leaflet.
Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medical product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Elanco GmbH

7. MARKETING AUTHORISATION NUMBER(S)

8. DATE OF FIRST AUTHORISATION

Date of first authorisation: {DD/MM/YYYY}

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

{MM/YYYY}

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary product subject to veterinary prescription.
Administration under the control or the direct responsibility of a veterinary surgeon.

Detailed information on this veterinary medicinal product is available in the Union Product Database (https://medicines.health.europa.eu/veterinary).

ANNEX III

LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE
Lithographed carton boxes

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

MIPREPOL 20 mg/ml + 4.48 mg/ml + 0.5293 mg/ml cutaneous suspension/ear drops, suspension (IT)
SUROLAN 20 mg/ml + 4.48 mg/ml + 0.5293 mg/ml cutaneous suspension/ear drops, suspension (ES, PT)

2. STATEMENT OF ACTIVE SUBSTANCES

20	mg/ml	Miconazole (as nitrate)
4.48	mg/ml	Prednisolone (as acetate)
0.5293	mg/ml	Polymyxin B sulfate

3. PACKAGE SIZE

15 ml
30 ml

4. TARGET SPECIES

Dogs and cats

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Cutaneous and auricular use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}
Once opened use within 3 months.

9. SPECIAL STORAGE PRECAUTIONS

Do not store above 25 °C.
Store in the original container.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Elanco GmbH

14. MARKETING AUTHORISATION NUMBERS

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

15 ml bottle; 30 ml bottle

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

MIPREPOL (IT)
SUROLAN (ES, PT)

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

20	mg/ml	Miconazole (as nitrate)
4.48	mg/ml	Prednisolone (as acetate)
0.5293	mg/ml	Polymyxin B sulfate

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}
Once opened use within 3 months.

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

MIPREPOL 20 mg/ml + 4.48 mg/ml + 0.5293 mg/ml cutaneous suspension/ear drops, suspension for dogs and cats (IT)
SUROLAN 20 mg/ml + 4.48 mg/ml + 0.5293 mg/ml cutaneous suspension/ear drops, suspension for dogs and cats (ES, PT)

2. Composition

Each ml contains:
Active substances:
20 mg Miconazole (as nitrate)
4.48 mg Prednisolone (as acetate)
0.5293 mg Polymyxin B sulfate
White suspension.

3. Target species

Dogs and cats

4. Indications for use

Dogs and cats: topical treatment of otitis externa and skin infections caused by the following susceptible species:

Fungi and yeasts
Microsporum spp
Trichophyton spp.
Candida spp.
Malassezia pachydermatis
Gram-positive bacteria
Staphylococcus spp.
Streptococcus spp.
Gram-negative bacteria
Pseudomonas spp.
Escherichia coli

In the case of external otitis due to ear mites (*Otodectes cynotis*), the effect of this product is due to a physical action of its excipient and not to the intrinsic activity of the active substances. Its use in this indication has to be chosen only when there is a secondary infection caused by susceptible organisms.

The product also has anti-inflammatory and anti-pruritic activity.

5. Contraindications

Do not use in animals with perforated ear drums since Polymixin B is known to be a potential ototoxic agent.
Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

6. Special warnings

Special warnings:
This veterinary medicinal product does not contain any antimicrobial preservative.

Special precautions for safe use in the target species:
For external use only.

Whenever possible, the veterinary medicinal product should only be used based on susceptibility testing.
Official, national and local antimicrobial policies should be taken into account when the product is used.
Use of the product deviating from the instructions given in the SPC may increase the prevalence of resistant bacteria, fungi or yeasts to polymixin B or miconazole respectively.

Before the product is applied, the external auditory canal must be examined to ensure that the eardrum is not perforated in order to avoid the risk of transmission of the infection to the middle ear and to prevent damage to the cochlear and vestibular apparatus.
After recovery, ears should be checked at regular intervals for signs of reinfection.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
- In case of accidental contact with eyes, seek medical advice immediately and show the package leaflet or the label to the physician.
- People with known hypersensitivity to the active substances should avoid contact with the veterinary medicinal product.
- Personal protective equipment consisting of single use disposable gloves should be worn when handling the veterinary medicinal product.
- The veterinary medicinal product should not be administered by pregnant women.

Pregnancy and lactation:
Can be used during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction:
None known.

Overdose:
No data available. Do not exceed the recommended dosage.

Major incompatibilities:
None known.
Avoid concomitant use with other topical products.

7. Adverse events

Dogs and cats:

Very rare (<1 animal / 10,000 animals treated, including isolated reports):
Deafness[1,2], hearing decreased[2] Hypersensitivity or Allergic reaction[3]

[1]Mainly in elderly dogs. If this occurs, treatment should be stopped.
[22] Reversible in the majority of cases.
[3]May occur, to any of the active substances or excipients

Long-term use of topical corticosteroids may cause very rare local or systemic effect, including skin thinning and delay wound healing. Their immunosuppressant actions may weaken resistance to or exacerbate existing infections.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system.

8. Dosage for each species, routes and method of administration

For topical administration.
Ears:
Clean the auditory canal and place 3-5 drops of the product into the ear twice daily.
Massage the ear and the auditory canal gently but thoroughly to ensure proper distribution.
For infections caused *by Otodectes cynotis*, instill five drops twice daily for 14 days.

Skin:
Having ensured the area to be treated is clean, apply a few drops of the product (depending on lesion size) twice a day. Wear single use disposable gloves and rub well.

Treatment should be continued until a few days after complete disappearance of the clinical symptoms. In some obstinate cases, treatment may be required for 2 to 3 weeks.

9. Advice on correct administration

Shake the bottle well before use.
At the beginning of treatment, hair surrounding or covering the lesions must be clipped; this should be repeated during treatment if necessary.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.
Do not store above 25°C.
Store in the original container.
Do not use this veterinary medicinal product after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.
Shelf life after first opening the container: 3 months.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste. Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required. These measures should help to protect the environment.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems applicable to the veterinary medical product concerned.

13. Classification of veterinary medicinal products

Veterinary product subject to veterinary prescription.
Administration under the control or the direct responsibility of a veterinary surgeon.

14. Marketing authorisation numbers and pack sizes

LDPE squeeze dropper bottle of 15 ml or 30 ml with a screw cap.
LDPE bottle of 15 ml or 30 ml with squeeze dropper in thermoplastic elastomer and child resistant screw cap in HDPE.
Lithographed carton boxes together with the package leaflet.
Not all pack sizes may be marketed.

15. Date on which the package leaflet was last revised

{MM/YYYY}

Detailed information on this veterinary medicinal product is available in the Union Product Database.

16. Contact details

Marketing authorisation holder and contact details to report suspected adverse reactions:
Elanco GmbH, Heinz-Lohmann-Str. 4, 27472 Cuxhaven, Germany
Manufacturer responsible for batch release:
Lusomedicamenta, Sociedade Técnica Farmacéutica, SA
Estrada Consiglieri Pedroso, 66, 69-B
Queluz de Baixo
2730-055 Barcarena (Portugal)

17. Other information